EDSA
EDSAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOperating under the Biotechnology umbrella, EDSA is a healthcare company. Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and. The company carries a $45.6M market cap, placing it firmly in the micro-cap category. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Market Cap
$45.6M
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.71
EPS (Fwd)
—
ROE
-122.9%
ROA
-66.4%
Cash
$10.3M
Total Debt
$0
Free CF
-$4.0M
52W Change
94.7%
Annual Financials
Cash vs Debt
Where EDSA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, EDSA finished 26.54% below its 150-day moving average ($6.48) and 9.33% below its 200-day moving average ($5.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EDSA overbought or oversold?
At the September 3, 2026 close, EDSA's RSI(14) was 38.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
EDSA reports $10.3M in cash and $0 in total debt. Free cash flow is running at -$4.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -122.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing EDSA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.